Sintilimab

Gastric Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors for the disease.

Adding sintilimab to chemotherapy improved survival compared with placebo among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, phase 3 study results published in JAMA showed.

CHICAGO — When added to induction chemotherapy and concurrent chemoradiotherapy, sintilimab conferred a 41% reduction in risk for disease recurrence or death among patients with high-risk locoregionally advanced nasopharyngeal carcinoma.

In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.

The FDA issued a complete response letter indicating it cannot approve a biologics license application for sintilimab in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer.

The FDA should not make a regulatory decision on sintilimab for advanced lung cancer until additional study demonstrates applicability to U.S. patients, an advisory committee determined.

The addition of sintilimab to chemotherapy prolonged PFS for patients with pretreated EGFR-mutated nonsquamous non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

The addition of sintilimab to first-line chemotherapy extended OS among patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results of a randomized phase 3 trial.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Adding sintilimab to gemcitabine and platinum improved PFS as first-line treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, according to a study published in Journal of Thoracic Oncology.